Pfizer (PFE) CEO Albert Bourla Receives Award of 21 Phantom Shares

What Happened Albert Bourla, Chairman & CEO (and director) of Pfizer Inc. (PFE), was granted 21 units that represent phantom shares of Pfizer common stock on August 31, 2026. The units are recorded at $28.46 each for a total value of $598. The transaction is an award/grant (derivative) rather than an open‑market purchase.

Key Details

• Transaction type: Award/Grant (code A) — derivative phantom share units.
• Transaction date: 2026-08-31; Form 4 filed: 2026-09-01 (timely).
• Price per unit: $28.46; total value: $598.
• Shares owned after transaction: Not specified in this filing.
• Footnotes: F1 — each unit equals one phantom share; F2 — units were granted under the Pfizer Nonfunded Deferred Compensation and Supplemental Savings Plan and are cash‑settled upon separation from service; units may be moved into an alternative investment account at any time.
• No indication of a 10b5-1 plan, tax withholding, or sale tied to this grant in this filing.

Context This grant represents deferred compensation (phantom shares) that will be settled in cash when the reporting person leaves service, so it is a compensation award rather than a direct purchase or sale of common stock. Such grants are common for executives and do not necessarily signal a bullish or bearish view by the insider.